Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study-Reference-Cited by-同舟云学术

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Published:2022-06-22 Issue:10 Volume:63 Page:2383-2392
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Yimer Habte¹,Melear Jason²,Faber Edward³,Bensinger William I.⁴,Burke John M.⁵,Narang Mohit⁶,Stevens Don⁷,Gray Kathleen S.⁸,Lutska Yana⁸,Bobba Padma⁸,Qi Keqin⁹,Hoehn Daniela⁸,Qi Ming¹⁰,Lin Thomas S.⁸,Rifkin Robert M.¹¹

Affiliation:

1. Texas Oncology, Tyler/US Oncology Research, Tyler, TX, USA

2. Texas Oncology, Austin, TX, USA

3. Oncology Hematology Care, Inc, Cincinnati, OH, USA

4. Swedish Cancer Institute, Seattle, WA, USA

5. US Oncology Research, Rocky Mountain Cancer Centers, Aurora, CO, USA

6. US Oncology Research, Maryland Oncology Hematology, Columbia, MD, USA

7. Norton Health Care, Louisville, KY, USA

8. Janssen Scientific Affairs, LLC, Horsham, PA, USA

9. Janssen Research & Development, LLC, Titusville, NJ, USA

10. Janssen Research & Development, LLC, Spring House, PA, USA

11. US Oncology Research, Rocky Mountain Cancer Centers, Denver, CO, USA

Funder

Error! Hyperlink reference not valid.

Austin Horton, PhD, and Charlotte D. Majerczyk, PhD, of Cello Health Communications/MedErgy

Janssen Global Services, LLC

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2076847

Reference39 articles.

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V2.2022.© National Comprehensive Cancer Network, Inc. 2021. All rights reserved. [cited 2021 Oct 22]. To view the most recent and complete version of the guideline, go online to NCCN.org.

2. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

3. Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

4. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

5. The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16;Blood Advances;2024-07-12

2. Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China;Cancer Medicine;2024-05

3. Management of Newly Diagnosed Multiple Myeloma Today, and in the Future;Hematology/Oncology Clinics of North America;2024-04

4. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma;Blood Reviews;2023-09

5. Role of daratumumab in the frontline management of multiple myeloma: a narrative review;Expert Review of Hematology;2023-08-18